To evaluate the efficacy of nontransplant surgery for pediatric cholestasis, 58 clinically diagnosed children, including 20 with Alagille syndrome (ALGS), 16 with familial intrahepatic cholestasis-1 (FIC1), 18 with bile salt export pump (BSEP) disease, and 4 others with low c-glutamyl transpeptidase disease (levels <100 U/L), were identified across 14 Childhood Liver Disease Research Network (ChiLDReN) centers. Data were collected retrospectively from individuals who collectively had 39 partial external biliary diversions (PEBDs), 11 ileal exclusions (IEs), and seven gallbladder-to-colon (GBC) diversions. Serum total bilirubin decreased after PEBD in FIC1 (8.1 6 4.0 vs. 2.9 6 4.1 mg/dL, preoperatively vs. 12-24 months postoperatively, respectively; P 5 0.02), but not in ALGS or BSEP. Total serum cholesterol decreased after PEBD in ALGS patients (695 6 465 vs. 457 6 319 mg/dL, preoperatively vs. 12-24 months postoperatively, respectively; P 5 0.0001). Alanine aminotransferase levels increased in ALGS after PEBD (182 6 70 vs. 260 6 73 IU/L, preoperatively vs. 24 months; P 5 0.03), but not in FIC1 or BSEP. ALGS, FIC1, and BSEP patients experienced less severely scored pruritus after PEBD (ALGS, 100% vs. 9% severe; FIC1, 64% vs. 10%; BSEP, 50% vs. 20%, preoperatively vs. >24 months postoperatively, respectively; P < 0.001). ALGS patients experienced a trend toward greater freedom from xanthomata after PEBD. There was a trend toward decreased pruritus in FIC1 after IE and GBC. Vitamin K supplementation increased in ALGS after PEBD (33% vs. 77%; P 5 0.03). Overall, there were 15 major complications after surgery. Twelve patients (3 ALGS, 3 FIC1, and 6 BSEP) subsequently underwent liver transplantation. Conclusion: This was a multicenter analysis of nontransplant surgical approaches to intrahepatic cholestasis. Approaches vary, are well tolerated, and generally, although not uniformly, result in improvement of pruritus and cholestasis. (HEPATOLOGY 2017;65:1645-1654.
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S urgical interruption of the enterohepatic circulation using partial external biliary diversion (PEBD) has been a mainstay of treatment for cholestatic syndromes, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) disease, for more than two decades. ALGS is an autosomal-dominant disorder characterized by multiorgan involvement, including significant cholestasis. Histologically, a paucity of bile ducts and diminutive portal tracts are observed in the liver. Even though bile synthesis by individual hepatocytes is not impaired, diminished access to draining bile ducts may cause reflux of bile into plasma.
(1) The physiological consequence is canalicular and intracellular cholestasis with slow progression to irreversible liver damage in up to 20% of ALGS patients. (2) The PFIC syndromes are a group of autosomal-recessive inherited disorders of impaired biliary transport and excretion. In most affected patients, symptoms of cholestasis begin in infancy and can eventually progress to cirrhosis and hepatic failure during the first decade of life. (3) (4) (5) A subset of PFIC patients have characteristically low serum c-glutamyl transpeptidase (GGTP) levels (<100 U/L), as a result of defects in either the gene ATP8B1, known previously as PFIC1 but now as familial intrahepatic cholestasis-1 (FIC1), the gene ABCB11, known previously as PFIC2 but now more descriptively as bile salt export pump (BSEP) disease, or other as yet unidentified genes. (6, 7) Although biliary diversion was described as a treatment for nonobstructive cholestatic liver disease as early as the 1930s, Whitington et al. described its use in the treatment of children with intractable pruritus from cholestasis by utilizing a jejunal conduit to externally drain the gallbladder (Fig. 1A) . (8) (9) (10) (11) Since then, numerous studies have demonstrated the short-term efficacy of PEBD at improving pruritus and laboratory parameters in patients with PFIC. (12, 13) PEBD has been demonstrated to improve histology and fibrosis in PFIC. (13, 14) Patients with ALGS have been noted to have improvement in pruritus, xanthomata, serum bile acids, and serum cholesterol with PEBD. (2, 15) Numerous other nontransplant surgical procedures have since been described, all aimed at interrupting the enterohepatic circulation with the potential for alteration in the bile acid pool. Chief among these alternative procedures are an ileal exclusion (IE; Fig. 1B) , which internally bypasses 15% of the terminal ileum, (16, 17) and an internal biliary diversion, which entails connecting the gallbladder either directly to the colon or utilizing a segment of jejunum as a conduit (gallbladder to colon [GBC]; Fig. 1C) . (18) (19) (20) Each operation provides a variable degree of symptom relief. Side effects of internal diversion include choleretic diarrhea, caused by a large amount of bile salt entering the colon directly, and malabsorption. Given the systemic manifestations that occur in FIC1 disease and persist posttransplantation, PEBD is a preferred treatment in this condition. (17, 21, 22) Unfortunately, particularly in BSEP disease, this surgery does not completely reverse the course of the disease, and many children still progress to liver transplantation (LT). (23) Additionally, PEBD, performed for BSEP disease, has not been protective against development of hepatocellular carcinoma, cholangiocarcinoma, or pancreatic adenocarcinoma. (24) (25) (26) Although numerous, most studies reporting outcomes of PEBD, internal biliary diversion, and IE involve a single center with some reporting the outcomes of only a single surgeon. Furthermore, the ability to analyze outcomes as a function of specific genetic diagnosis has only recently become available. A crosssectional analysis of the different procedures across a wide range of centers is lacking. No trials to date have performed a head-to-head comparison to evaluate the outcomes of the various surgical techniques. (27) Herein, we report a multicenter retrospective analysis of outcomes of nontransplant surgery in PFIC and ALGS.
Patients and Methods
The Childhood Liver Disease Research Network (ChiLDReN) is a National Institute of Diabetes, Digestive, and Kidney Diseases/National Institute of Health-funded research consortium of 15 North American pediatric centers with the goal of understanding the etiology, pathogenesis, course, and outcomes of several pediatric cholestatic conditions. Among 14 ChiLDReN centers, 58 children were identified with the clinicopathological diagnoses of ALGS, FIC1, and BSEP disease or indeterminate low GGTP intrahepatic cholestasis (GGTP, <100) who underwent nontransplant surgical intervention for cholestasis between 2005 and 2013. Institutional review board approval was obtained at each participating hospital. Diagnostic criteria were according to local standards at the ChiLDReN clinical center and may not have included genotyping, which was not readily available for most patients. Data were retrospectively collected at these centers into a central database, using REDCap administered at the University of Southern California (PI: K.S.W.). Demographic and clinical data were collected including medications, laboratories, and symptoms during four time periods (-6 to 0 months preoperatively, 6 to 12 months postoperatively, 12 to 24 months postoperatively, and greater than 24 months postoperatively). Given the retrospective nature of the data collection, pruritus grading was simplified from a scoring system described by Emerick and Whitington, (2) where reported and recorded, as either as absent, mild to moderate (not impairing sleep and school work), or severe (mutilating, impairing sleep and school work). Xanthomata were graded as present or absent. Longitudinal laboratory data were log-transformed as needed to normalize distributions and analyzed with repeated-measures mixed models. Categorical longitudinal data were analyzed using generalized estimating equations or Wilcoxon's signed-rank test for comparing preoperative to mean of postoperative values.
STATISTICAL ANALYSIS
Statistical tests were performed using SAS/STAT (Cary, North Carolina, USA) software (version 9.2), at a two-sided 0.05 significance level.
Results
Fifty-eight patients who underwent surgical intervention for cholestasis were identified. This included 20 patients clinically diagnosed with ALGS, 16 with FIC1, 18 with BSEP, and 4 others with GGTP levels <100 U/L.
PREOPERATIVE DEMOGRAPHICS AND CLINICAL MANIFESTATIONS
Of the 20 ALGS patients, 11 (55%) were male (Supporting Table S1 ). The majority of ALGS patients were white (60%) and non-Hispanic (85%). ALGS patients underwent surgery at a median age of 30 months (Q1/Q3 5 26/86 months; range 5 2 to 218; mean 5 65). In terms of clinical features of ALGS, histological bile duct paucity was noted in 16 (80%), clinical evidence of cholestasis in 19 (95%), cardiac defects in 16 (80%), skeletal abnormalities in 6 (30%), and characteristic facial features in 18 (90%). Preoperative complications of ALGS included patients with rickets (3 patients, 1 of whom had a fracture), ascites (1 patient), and failure to thrive requiring either enteral or parenteral nutritional supplementation (4 patients; Supporting Table S2 ). Indications for surgical diversion included severe pruritus (100%), xanthomata (50%), and progression of liver disease (25%). Information regarding mutations in JAGGED1 was available in the charts of 7 patients (35%). In addition to bile duct paucity, preoperative histological findings included giant cell transformation in 6 (30%). Ishak fibrosis scores were available in 15 patients (75%), with a mean of 1.9 6 1.7.
Of the 38 PFIC patients (16 FIC1, 18 BSEP, and 4 others with GGTP <100), 14 (38%) were male (Table  1) . Seventy-five percent of PFIC patients were white and 85% were non-Hispanic. PFIC patients underwent surgery at a median age of 18 months (Q1/Q3 5 11/28 months; range 5 6 to 228; mean 5 28). Preoperative complications of the 16 FIC1, 18 BSEP, and 4 patients with GGTP <100 are listed in Supporting  Table S1 . Among the 38 PFIC patients, indications for surgical diversion included pruritus (92%) and progression of liver disease (59%). Information regarding ATP8B1 mutations was noted in the charts of 8 FIC1 patients (50%), and ABCB11 mutations were noted in the charts of 11 BSEP patients (61%) (Supporting Table S3 ). No data regarding mutations were available in the 4 other patients with GGTP <100 who were not classified as ALGS, FIC1, or BSEP.
SURGICAL INTERVENTION AND COMPLICATIONS
Of the 58 patients, 40 (15 ALGS, 13 FIC1, 11 BSEP, and 1 GGTP <100) underwent PEBD, 11 (5 ALGS, 1 FIC1, 2 BSEP, and 3 GGTP <100) underwent an internal IE, and 7 (1 ALGS, 3 FIC1, 3 BSEP, and 0 GGTP <100) underwent internal biliary diversion from GBC.
Of the 20 ALGS patients in the study, 15 underwent PEBD. Fourteen patients underwent continuous gallbladder drainage to an external stoma through a conduit of jejunum outside of gastrointestinal continuity. In 1 patient, the appendix was used as a conduit for external drainage. Five ALGS patients underwent internal bypass. Specifically, 4 underwent IE, with bypass 15% of the jejunal/ileal length from the ileocecal valve with anastomosis of proximal ileum to the right colon. One patient underwent partial internal biliary diversion through GBC.
Of the 37 PFIC patients, 25 underwent PEBD. Two of these patients underwent creation of cholecystocutaneous fistulae, which were intubated with Mic-Key gastrostomy devices (Halyard Health, Alpharetta, GA) for intermittent drainage; all others had continuous drainage through jejunal conduits. Five patients underwent 15% IE. One underwent 40% IE. Six patients underwent GBC.
Among the 40 PEBD, complications included 1 patient with intestinal ischemia, 3 with stoma prolapses, and 1 with bowel obstruction and four episodes of dehydration/electrolyte derangements (Supporting Table S4 ). Among the 11 IE, there were 2 patients with dehydration/electrolyte derangements. Among 
POSTOPERATIVE OUTCOMES
Serum laboratory data were analyzed across the various cholestatic diseases in this study after PEBD and IE (Table 1) . Following PEBD, neither ALGS nor BSEP patients experienced a significant decrease in serum total bilirubin (ALGS: 0 5 5.3 6 5.4, 24 months 5 4.9 6 4.1 mg/dL; Fig. 1 ; BSEP: 0 5 2.7 6 2.9, 24 months 5 2.1 6 2.5 mg/dL). In contrast, FIC1 patients undergoing PEBD experienced a significant decrease in serum total bilirubin (0 5 8.1 6 4.0, 24 months 5 2.9 6 4.1 mg/dL; P 5 0.0004; Fig. 1 ). Total serum cholesterol decreased in ALGS patients undergoing PEBD (0 5 695 6 465, 12 months 5 365 6 152, 24 month 5 457 6 319 mg/dL; P 5 0.02). Alanine aminotransferase (ALT) levels increased in ALGS patients after PEBD (0 5 182 6 70, 24 months 5 260 6 73 IU/L; P 5 0.03), but not significantly different in FIC1 (0 5 113 6 134, 24 months 5 56 6 32) or BSEP patients (0 5 123 6 112, 24 months 5 99 6 83). In our cohort of patients, total serum bile acid measurements were not commonly performed. There were, however, nonsignificant trends toward a reduction in total serum bile acid levels in both FIC1 and BSEP patients following PEBD (FIC1: 0 5 163 6 68, 12 months 5 21 6 12, >24 months 5 46 6 76 micromole/dL and BSEP: 0 5 355 6 158, 12 months 5 191 6 154, 24 months 5 203 6 75, >24 months 5 182 6 62 micromole/dL). Notably, in 3 FIC1 patients for whom serum total bile acids were measured preoperatively and postoperatively, there were dramatic reductions in serum total bile acids in FIC1 patients following PEBD (0 5 196 6 59, 12 months 5 19 6 11, 24 months 5 7 6 2 micromole/dL). All 3 reported complete resolution of severe pruritus. In 2 ALGS patients with measurements before and after PEBD, there were dramatic reductions in serum total bile acids (patient A: 0 5 277, 12 months 5 108 micromole/dL; patient B: 0 5 254, 12 months 5 60 micromole/dL); both likewise had complete resolution of severe pruritus. In contrast, the 2 BSEP patients with decreased postoperative serum total bile acid measurements compared to preoperative levels did not experience any improvement in pruritus. No differences in total bilirubin, ALT, alanine aminotransferase levels were detected over 24 months postoperatively in FIC1, BSEP, ALGS, and GGTP <100 patients undergoing IE ( Table 2) .
Degree of postoperative pruritus was collected where available. When analyzed in aggregate, the fraction of ALGS, FIC1, and BSEP patients with reported mildto-moderate or severe pruritus after PEBD decreased compared to preoperative (ALGS: 0 5 100% with severe pruritus, >24 months 5 9%; FIC1: 0 5 64% vs. >24 months 5 10%; BSEP: 0 5 50% vs. >24 months 5 20%; P < 0.0001 for all diagnoses; Fig. 2) . A trend toward greater freedom from xanthomata was also observed postoperatively in ALGS patients (0 5 50%, >24 months 5 75%; P 5 0.125). Before IE, 5 of 5 ALGS patients experienced severe pruritus. At 6-12 months, 2 of 5 still experienced severe pruritus; none reported severe pruritus at 12-24 months, suggesting some benefit surgically. None of the 5 ALGS undergoing IE experienced resolution of xanthomata postoperatively through 24 months.
In terms of medication usage (yes vs. no) in patients with ALGS after PEBD, there were no significant changes in reported medication usage, but there were trends toward decreases in the use of cholestyramine (47% preoperatively vs. 14% >24 months postoperatively; P 5 0.09) and rifampin (60% preoperatively vs. 36% >24 months postoperatively; P 5 0.125). There was no reported change in the use of ursodeoxycholic acid, opioid antagonists, vitamin E, combination fatsoluble vitamins, or diuretics. There was a reported increase in usage of vitamin K (33% preoperatively vs. 77% >24 months postoperatively; P 5 0.03) and a trend toward an increase in usage of vitamin D (53% preoperatively vs. 92%, >24 months postoperatively; P 5 0.125).
Eleven patients (5 ALGS, 1 FIC1, 2 BSEP, and 3 GGTP <100) underwent IE. Five of 5 ALGS patients had severe pruritus before IE and 1 of 4 still had it at 12 months postoperatively; no change was observed in xanthomata (5 of 5 at both 0 and 12 months). No clear trend in terms of severe pruritus was noted in FIC1/BSEP patients (0 5 3 of 5, 12 months 5 1 of 3, 24 months 5 1 of 2). Two patients with GGTP <100 who had undergone IE subsequently underwent revision to PEBD attributed to persistent severe pruritus. Both had improvement of symptoms postrevision.
Seven patients (1 ALGS, 3 FIC1, 3 BSEP, and 0 GGTP <100) underwent GBC diversion with evidence of reduced post-GBC pruritus (0 5 7 of 7, 12 months 5 0 of 6, 24 months 5 3 of 6).
There was 1 death reported within the network. 
Discussion
The indications for and outcomes of nontransplant surgical interventions for intrahepatic cholestasis are not well delineated. Most of the published literature is single centered and subject to potential bias toward positive results. (2, 5, 8, 9, 15, 16, (18) (19) (20) 27, 28) The current study was designed to be cross-sectional, multicentered, and unbiased toward outcomes with an intent to give a real-world view of this complicated area of surgical therapy. In this study, we analyzed retrospectively collected data on patients with ALGS or PFIC who underwent PEBD, IE, or GBC procedures for relief of pruritus and xanthomata at 14 centers with expertise in this area. Not surprisingly, there was considerable variability in the surgical approaches undertaken at the 14 centers. PEBD remains the most commonly used approach. A significant reduction in serum total bilirubin was observed following PEBD in FIC1 patients, but not in ALGS or BSEP patients. Serum total cholesterol decreased in ALGS patients after PEBD. Symptomatically, ALGS, FIC1, and BSEP patients experienced less pruritus after PEBD. ALGS patients exhibited a trend toward reduced xanthomata burden as well. A reduction in the use of antipruritus medications was observed in ALGS after PEBD, consistent with improved symptomatology. There were insufficient numbers of patients undergoing IE or GBC procedures to draw any significant conclusions; however, there were trends toward improvements in symptomatology following each of these procedures as well. These results were consistent with, but perhaps not as dramatic as, the existing published literature. Incomplete and transient responses were reported in many cases.
There are a variety of complex unresolved issues that face clinicians considering the use of nontransplant surgery for the treatment of intrahepatic cholestasis. There are a number of surgical options available, and it is unclear whether they are all equivalent in both the expected outcome and the potential risks associated with the procedures. PEBD is the classic approach and has the longest track record. It can be associated with excellent outcomes and appears to be relatively safe. The fraction of bile that is diverted to the ostomy is variable and not easily controlled. Excessive diversion can be associated with fluid and electrolyte issues along with nutritional problems related to decreased luminal bile acids. The increased use of vitamin K after PEBD in ALGS may reflect this issue. Inadequate diversion will likely be ineffective. Given low patient satisfaction with a permanent ostomy, alternative approaches have been developed, including IE and "internal" diversion to the colon. The relative efficacy of all these approaches remains uncertain, and the current investigation was not adequately powered to provide a definitive answer. IE can be complicated by the potential for diarrhea attributed to uncertainty in determining the appropriate amount of ileum to be excluded. "Internal" diversion can also be complicated by diarrhea. Both alternatives have the potential of long-term cancer risk associated with bile flowing directly into the colon. (29) Differences in response to surgery in PFIC relative to ALGS in this study support the notion that diseasespecific responses exist. Likely, not all cholestasis is the same. In fact, there may be genotypic differences in response given that more-severe defects (nonsense and deletions) in ABCB11 are less likely to respond to surgery compared to less-severe missense mutations. (30) One might hypothesize that the response to surgery relates to specific interruption of the enterohepatic circulation of bile acids. This hypothesis is currently being tested in ongoing studies of a pharmacological inhibitor of intestinal reabsorption of bile acids (e.g., NCT 01903460, 02057718, 02057692, and 02160782). A significant amount of the published literature on nontransplant surgery predated the identification of the molecular basis of different forms of cholestasis and the routine use of relevant genotyping. In this analysis, genotyping was not readily available for most patients. In many instances, genotyping was likely not covered by insurance and therefore was not performed. Thus, a clear analysis of genotype and response to surgery was not possible. Assessing indications for, and outcomes of, surgery becomes remarkably complicated when one subdivides on the basis of (1) type of surgery, (2) genetic defect, (3) severity of the genetic defect, and (4) stage of disease at the time of surgery.
The current study suggests that outcomes are much more complicated than one might glean from the existing published literature. Emerick et al. demonstrated that ALGS patients at baseline had greater bile salt, cholesterol, phospholipid, and chenodeoxycholicto-cholic acid ratios than PFIC patients. (31) They also showed that following successful PEBD, ALGS patients have higher biliary lipid concentrations than PFIC patients, and that the FIC1 subtype of PFIC was associated with increased postoperative biliary phospholipic concentrations. Jericho et al. studied the kinetics of bile acid turnover in 5 PFIC patients with successful PEBD compared to 5 PFIC patients who underwent LT (32) and observed comparable bile acid transport kinetics between the two groups. The researchers postulated that the PEBD causes a shift to a relatively more hydrophilic bile acid pool composition that is less damaging to liver parenchyma and thus alleviates cholestasis. In our study, we observed PEBD to be effective for some patients with either FIC1, BSEP, or ALGS. We posit that similar mechanisms of action result in relief of pruritus and xanthomata in ALGS. Our data suggest some efficacy as well with IE, and although the mechanism of action here is unstudied, there is likely a similarly bile acid turnover and pool composition change associated with relief of symptoms.
Conduct of a prospective, randomized trial comparing outcomes of children who have undergone nontransplant surgery for cholestasis will be nearly impossible. It is likely to be underpowered and unacceptable to providers, patients, and their families. The current investigation highlights the complexity of this question. Because LT can be problematic for many of these disorders, identifying the appropriate patient for the appropriate operation would be ideal. (33) (34) (35) (36) A prospective, multicenter, multinational registry would be most likely to provide further insights into this important issue. Such a registry will need to be multicentered and will need to carefully account for the type of surgery, genotype of the disease, and stage of disease at the time of surgery. Prospective follow-up of complications and outcomes is critical for a valid assessment.
In summary, we found that, in an experience representing multiple institutions specializing in the care of children with intrahepatic cholestasis, biliary diversion is an effective option for patients without cirrhosis with pruritus who are refractory to medical management. Responses to therapy are complex, with variability in the completeness of the response. Further acquisition of prospective multicentered data in a systematic manner is required to better understand the full scope of the indications for, and outcomes of, nontransplant surgery for intrahepatic cholestasis.
